Table 2.
Distant metastasis-free survival, disease-specific survival and overall survival stratified according to sex, site of melanoma, ulceration status, disease burden at in-transit metastases (ITM) diagnosis, adjuvant systemic therapy use, Breslow thickness, age at ITM diagnosis, ITM-free interval, ITM count at diagnosis, and size of the largest ITM at diagnosis (n = 142)
| Survival endpoint | Disease specific | Distant metastasis–free | Overall | |||
|---|---|---|---|---|---|---|
| Crude risk | Adjusted riska | Crude risk | Adjusted riska | Crude risk | Adjusted riska | |
| Sex | ||||||
| Female | Referent | Referent | Referent | Referent | Referent | Referent |
| Male |
1.59 (0.98–2.58) p = 0.059 |
1.29 (0.70–2.37) p = 0.409 |
1.85 (1.19–2.87) p = 0.006 |
1.29 (0.74–2.27) p = 0.371 |
1.37 (0.89–2.12) p = 0.155 |
1.07 (0.61–1.86) p = 0.822 |
| Site | ||||||
| Axial | Referent | Referent | Referent | Referent | Referent | Referent |
| Extremity |
0.92 (0.56–1.53) p = 0.725 |
1.28 (0.66–2.48) p = 0.458 |
0.66 (0.42–1.03) p = 0.068 |
1.29 (0.74–2.24) p = 0.369 |
0.93 (0.59–1.46) p = 0.740 |
1.15 (0.63–2.10) p = 0.640 |
| Ulceration | ||||||
| Absent | Referent | Referent | Referent | Referent | Referent | Referent |
| Present |
1.39 (0.86–2.25) p = 0.180 |
0.97 (0.55–1.68) p = 0.904 |
1.10 (0.71–1.70) p = 0.676 |
1.01 (0.61–1.68) p = 0.976 |
1.40 (0.91–2.17) p = 0.128 |
1.05 (0.63–1.74) p = 0.860 |
| Disease burden | ||||||
| Local | Referent | Referent | Referent | Referent | Referent | Referent |
| Regional |
1.14 (0.66–1.98) p = 0.640 |
1.21 (0.64–2.29) p = 0.559 |
2.45 (1.44–4.18) p = 0.001 |
2.61 (1.44–4.72) p = 0.002 |
1.07 (0.65–1.77) p = 0.782 |
1.22 (0.69–2.17) p = 0.501 |
| Distant |
1.75 (0.94–3.25) p = 0.079 |
1.84 (0.87–3.92) p = 0.112 |
– | – |
1.75 (1.00–3.05) p = 0.048 |
2.17 (1.10–4.29) p = 0.026 |
| Adjuvant systemic therapy | ||||||
| Not given | Referent | Referent | Referent | Referent | Referent | Referent |
| Given |
1.45 (0.87–2.41) p = 0.149 |
1.32 (0.75–2.32) p = 0.328 |
2.25 (1.38–3.64) p = 0.001 |
1.64 (0.97–2.77) p = 0.063 |
1.28 (0.81–2.00) p = 0.288 |
1.22 (0.74–2.00) p = 0.441 |
| Breslow thickness |
1.10 (1.04–1.17) p = 0.001 |
1.06 (0.98–1.14) p = 0.150 |
1.03 (0.97–1.09) p = 0.354 |
0.96 (0.89–1.05) p = 0.375 |
1.09 (1.03–1.15) p = 0.002 |
1.05 (0.98–1.13) p = 0.160 |
| Age at ITM diagnosis |
1.02 (0.99–1.04) p = 0.145 |
1.01 (0.99–1.04) p = 0.250 |
0.99 (0.97–1.01) p = 0.278 |
1.01 (0.99–1.03) p = 0.250 |
1.02 (1.00–1.04) p = 0.037 |
1.02 (1.00–1.05) p = 0.054 |
| ITMs-free interval |
0.99 (0.98–1.00) p = 0.027 |
0.99 (0.98–1.00) p = 0.094 |
1.00 (0.99–1.00) p = 0.702 |
1.00 (0.99–1.00) p = 0.130 |
0.99 (0.99–1.00) p = 0.040 |
0.99 (0.99–1.00) p = 0.125 |
| ITMs Count at Diagnosis |
1.25 (1.04–1.51) p = 0.020 |
1.09 (0.87–1.36) p = 0.439 |
1.43 (1.16–1.76) p = 0.001 |
0.90 (0.73–1.12) p = 0.363 |
1.19 (0.98–1.45) p = 0.074 |
1.04 (0.84–1.30) p = 0.715 |
| Size of the largest ITM at diagnosis (mm) |
1.01 (1.00–1.02) p = 0.106 |
1.00 (0.99–1.02) p = 0.502 |
1.02 (1.01–1.03) p = 0.002 |
1.02 (1.01–1.03) p < 0.001 |
1.01 (1.00–1.02) p = 0.064 |
1.00 (0.99–1.02) p = 0.406 |
Bold values indicate satistical significance P <0.05
Data are presented as hazard ratio (95% confidence interval)
a Variables were examined by Cox’s regression, adjusted for sex, site, ulceration status, disease burden, adjuvant systemic therapy use, Breslow thickness, age at ITM diagnosis, ITM interval, ITM count at diagnosis, and size of the largest ITM at diagnosis